Today: 11 June 2026
Browse Category

NYSE:JNJ 30 November 2025 - 14 December 2025

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Eli Lilly reported late-stage trial success for its obesity drug retatrutide, with patients losing 28.7% of body weight over 68 weeks. Pfizer re-entered the obesity drug market through a $150 million licensing deal with Yao Pharma. The FDA moved to accelerate review of Lilly’s oral GLP-1 pill, orforglipron, possibly advancing a decision to March. The Fed cut rates by 25 basis points and signaled new Treasury purchases.
14 December 2025
······
Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

Johnson & Johnson shares closed at $211.58 on Dec. 12, 2025, up 4.9% for the week after an FDA approval for AKEEGA in prostate cancer and new multiple myeloma data. The stock outperformed the broader market despite renewed talc litigation risk. A Federal Reserve rate cut earlier in the week supported large healthcare stocks. JNJ traded as high as $212.27 intraday Friday.
13 December 2025
··
Johnson & Johnson (JNJ) Stock News Today, Forecasts and Analyst Targets (Dec. 12, 2025)

Johnson & Johnson (JNJ) Stock News Today, Forecasts and Analyst Targets (Dec. 12, 2025)

Johnson & Johnson shares traded at $210.50 as of 14:33 UTC Friday, near Thursday’s all-time high close of $210.01. Wells Fargo and Morgan Stanley raised their price targets to $230 and $197, respectively, following similar moves by RBC, Citigroup, and HSBC. The average analyst target now sits just above the current price, with consensus ratings holding at “overweight.”
12 December 2025
·
Johnson & Johnson (JNJ) Stock Near Record Highs: Latest News, Legal Risks and 2026 Outlook for Investors

Johnson & Johnson (JNJ) Stock Near Record Highs: Latest News, Legal Risks and 2026 Outlook for Investors

Johnson & Johnson stock hit a 52-week high of about $208 on December 11, 2025, lifting its market cap above $500 billion after a rally that outpaced the S&P 500. The surge followed strong oncology trial results, new drug approvals, and optimism about offsetting Stelara sales declines. Legal risks and pricing pressures remain. JNJ’s dividend yield stands near 2.5%.
11 December 2025
·
Johnson & Johnson (JNJ) Stock After the Bell on December 10, 2025 – And What to Watch Before the December 11 Open

Johnson & Johnson (JNJ) Stock After the Bell on December 10, 2025 – And What to Watch Before the December 11 Open

Johnson & Johnson closed at $206.54 on Dec. 10, up 3.3% and less than 1% below its record high, after strong multiple myeloma drug data. After-hours trading edged the stock to $206.90, but premarket indications early Dec. 11 showed a drop to $202.50 on light volume. Year-to-date, JNJ has gained nearly 40%. The company faces ongoing talc litigation and regulatory scrutiny.
11 December 2025
··
Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Johnson & Johnson shares rose nearly 2% to about $204 on December 10, 2025, after new Phase 3 data showed its Tecvayli and Darzalex combo cut the risk of multiple myeloma progression or death by 83%. The company has filed for FDA approval, while investors weigh growth in oncology against ongoing talc litigation. JNJ stock is up over 38% year to date, outpacing healthcare peers.
10 December 2025
···
Johnson & Johnson (JNJ) Stock After Hours on December 9, 2025: New Cancer Breakthrough, Dividend Payout and What to Watch Before the December 10 Open

Johnson & Johnson (JNJ) Stock After Hours on December 9, 2025: New Cancer Breakthrough, Dividend Payout and What to Watch Before the December 10 Open

Johnson & Johnson shares closed at $199.96 on December 9, down 0.8% after touching $205.54 intraday. After the bell, the company reported Phase 3 data showing its TECVAYLI® + DARZALEX FASPRO® combination cut multiple myeloma progression or death risk by 83%. JNJ paid a $1.30 quarterly dividend, marking 63 years of dividend growth. Analyst consensus sees modest upside, with targets near $203–207.
10 December 2025
···
Johnson & Johnson Stock Today: Q3 Beat, Orthopaedics Spin-Off and New Cancer Data Power a 40% Rally

Johnson & Johnson Stock Today: Q3 Beat, Orthopaedics Spin-Off and New Cancer Data Power a 40% Rally

Johnson & Johnson shares closed at $201.62 on December 8, 2025, up nearly 40% year to date and valuing the company at about $486 billion. The stock surged after a Q3 earnings beat, raised full-year guidance, and a surprise plan to spin off its DePuy Synthes orthopaedics unit. JNJ remains a key driver of recent Dow gains. Technical models project up to 16% further upside by March 2026.
9 December 2025
··
Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly shares closed at $998 on December 8, down 1.3%, marking a seventh straight decline and leaving the stock about 10% below its recent high. The company reported a 15% dividend increase, secured Chinese reimbursement for Mounjaro, and saw Nobel laureate Carolyn Bertozzi return to its board. Competition and price cuts in weight-loss drugs weighed on the stock.
9 December 2025
······
Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Johnson & Johnson shares traded at $202.48 on December 8, 2025, near a 52-week high and up nearly 35% over the past year. The company raised its 2025 sales guidance to $93–94 billion and EPS to about $10.80–$10.90 after beating Q2 and Q3 expectations. Analysts’ 12-month targets average just above the current price, with a consensus “Buy” rating. J&J faces Stelara patent loss, talc lawsuits, and MedTech pricing pressure in China.
8 December 2025
··
Johnson & Johnson (JNJ) Stock Near Record Highs: What to Know Before the Market Opens on December 8, 2025

Johnson & Johnson (JNJ) Stock Near Record Highs: What to Know Before the Market Opens on December 8, 2025

Johnson & Johnson closed Friday at just over $201, near its 52-week high of $207.81, with a market cap around $486 billion. The company reported positive CAR-T therapy data at ASH 2025 and gained access to China’s new drug reimbursement catalog. The board declared a Q4 dividend of $1.30 per share. About 67,670 federal talc lawsuits remain unresolved after a judge rejected J&J’s latest $10 billion settlement offer.
8 December 2025
·
Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Johnson & Johnson Stock Today (JNJ): Price, Talc Verdicts, New Bladder Cancer Data and 2026 Outlook – December 6, 2025

Johnson & Johnson shares closed at $201.90 on December 5, 2025, less than 3% below their 52-week high. The stock has climbed about 35% over the past year, fueled by earnings beats, acquisitions, and new clinical data. The company faces large talc litigation verdicts and plans to spin off its orthopaedics unit. Market capitalization stands near $485 billion.
6 December 2025
··
Johnson & Johnson (JNJ) Stock on December 6, 2025: Price, Latest News, Analyst Targets and Dividend Outlook

Johnson & Johnson (JNJ) Stock on December 6, 2025: Price, Latest News, Analyst Targets and Dividend Outlook

Johnson & Johnson shares closed at $201.93 on December 5, 2025, near a record high after climbing about 35% over the past year. The stock’s 2025 rally outpaced major indexes, driven by strong earnings and portfolio changes, but ongoing talc litigation remains a risk. JNJ trades at roughly 19 times trailing earnings, with a market cap near $480 billion. Institutional ownership is close to 70%.
6 December 2025
·
Johnson & Johnson (JNJ) Stock: Price, Latest News, Analyst Forecasts and Dividend Outlook – December 5, 2025

Johnson & Johnson (JNJ) Stock: Price, Latest News, Analyst Forecasts and Dividend Outlook – December 5, 2025

Johnson & Johnson shares closed near $201 on December 5, 2025, up about 40% year-to-date and just below record highs. Guggenheim raised its price target to $227 after strong Q3 results and increased full-year guidance. Institutional ownership remains high amid ongoing litigation and a planned spinoff. Most analyst targets now cluster near current prices.
5 December 2025
·
Johnson & Johnson (JNJ) Stock on December 3, 2025: Analyst Upgrades, Options Signals and New Drug Wins at Near‑Record Highs

Johnson & Johnson (JNJ) Stock on December 3, 2025: Analyst Upgrades, Options Signals and New Drug Wins at Near‑Record Highs

Johnson & Johnson traded near $206 on Wednesday, close to its 52-week high after a 40% rally this year. Guggenheim reiterated a Buy rating and $206 target, citing strong multiple myeloma trial results. Barclays raised its target to $197 but kept an Equal Weight rating. The company launched a vision-care campaign with Naomi Watts and received European approval for its autoimmune drug IMAAVY.
4 December 2025
··
Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

Johnson & Johnson closed at $206.92 on December 2, just below its record high of $207.56 from November 26. The company’s market cap stands near $500 billion after a 30% year-to-date stock surge, outpacing the S&P 500. Recent gains follow strong earnings, higher 2025 guidance, a new EU drug approval, and a $3.05 billion oncology acquisition.
2 December 2025
··
Johnson & Johnson (JNJ) Stock Near Record Highs: What Investors Should Know Before the December 1, 2025 Market Open

Johnson & Johnson (JNJ) Stock Near Record Highs: What Investors Should Know Before the December 1, 2025 Market Open

Johnson & Johnson closed at $206.92 on Friday, just below its all-time intraday high of $207.81 set in late November. The stock has gained 17.6% over the past three months and 43.5% year-to-date, far outpacing the S&P 500. Market capitalization stands near $500 billion. Shares open December 1 with investors watching for new analyst commentary and ongoing legal and spin-off risks.
30 November 2025
·
1 … 5 6 7 8 9

Stock Market Today

  • Soybean Prices Rise Amid Anticipation for WASDE Report and Weather Impact
    June 11, 2026, 4:58 AM EDT. Soybeans posted gains of 8 to 11 cents across most contracts on Wednesday, with the national average cash bean price rising 12 cents to $10.70 3/4. Soymeal and soy oil futures also experienced notable increases. Heavy precipitation is expected in key Midwestern states, potentially affecting crop conditions. Traders are awaiting Thursday's World Agricultural Supply and Demand Estimates (WASDE) report, forecasting steady carryout levels for old and new crop soybeans. July and August 2026 soybean futures rose over 10 cents, reflecting market optimism ahead of the report. The weather outlook and WASDE figures remain critical factors driving market activity in soybean trading.

Latest articles

Oracle Stock Moves Higher as AI Backlog Draws Focus

Oracle shares fall after data center spending outlook hits, even as cloud backlog hits new high

11 June 2026
Oracle shares plunged 8.9% in after-hours trading as investors balked at the company’s plan to raise about $40 billion in debt and equity to fund a massive AI data center buildout, despite record revenue and a $638 billion backlog; free cash flow was negative $23.7 billion in fiscal 2026 as capital spending soared, intensifying concerns over whether AI demand will translate into durable profit.
Nvidia Gets AI Approval From Apple But Shares Stay Flat

Nvidia’s $91 Billion Slide Leaves AI Stocks Facing Pressure

11 June 2026
Nvidia plunged 3.73% to $200.42 as investors questioned whether its $91 billion quarterly revenue outlook can withstand rising rates, inflation, and China export restrictions; the selloff hit AI and semiconductor stocks broadly, despite Nvidia’s record sales, making its next quarter’s results a critical test for sustaining its high valuation.
MoneySimpler Moves Into AI Crypto Trading Bots As Market Fills Up

MoneySimpler Moves Into AI Crypto Trading Bots As Market Fills Up

11 June 2026
MoneySimpler launches an AI-powered trading automation platform integrating crypto, forex, and equities for retail users without coding skills, as competition intensifies over dashboard features and AI capabilities; no audited returns or user data disclosed, leaving adoption and real-world performance uncertain.
Go toTop